分享縮略圖
 

China-led study in atopic dermatitis treatment debuts

By Zhang Rui
0 Comment(s)Print E-mail China.org.cn, March 13, 2025
Adjust font size:

A major investigation into the real-world effects of the JAK1 inhibitor abrocitinib, in a study called the "Abrocitinib CHinese rEgistry on AD" (AHEAD), made its international debut at the 83rd Annual Meeting of the American Academy of Dermatology held March 7-11 in Orlando, Florida, where over 20,000 experts gathered.

The study's interim results offer strong real-world evidence for the use of selective JAK1 inhibitors in treating atopic dermatitis (AD), underscoring China's rising influence in global dermatology research and clinical standards.

Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) trials were also presented at the conference, offering new insights into abrocitinib's efficacy, safety and long-term benefits. These studies advance precision medicine for AD, providing critical data to guide clinical decisions and optimize treatment strategies.

"We are thrilled to present the interim findings of AHEAD on the global stage," said professor Gao Xinghua, leading principal investigator of AHEAD and director of the Department of Dermatology at the First Affiliated Hospital of China Medical University. "As the largest real-world study of JAK1 inhibitors in AD to date, AHEAD aggregates invaluable clinical data from diverse regions across China, helping refine treatment approaches for Chinese AD patients."

He continued, "Complementing international Phase III clinical trial evidence, AHEAD provides additional real-world insights into the use of innovative therapies like abrocitinib in China. The release of these interim results not only offers guidance for standardized diagnosis and treatment in China but also introduces fresh perspectives for global AD treatment guidelines and personalized medicine."

Jean-Christophe Pointeau, president of Pfizer China and executive committee member of R&D-based Pharmaceutical Association Committee (RDPAC), underscored the significance of the findings: "The release of the AHEAD and JADE studies strengthen clinical decision-making in China with evidence-based data while amplifying the 'Voice of Chinese Science' in global practice."

Pointeau highlighted Pfizer as the first biopharmaceutical company to pioneer JAK pathway research for inflammatory diseases, with three decades of innovation in JAK inhibitors. He said Pfizer remains committed to advancing post-launch R&D, supporting dermatology development in China, and collaborating with Chinese dermatologists to enhance global scientific contributions for AD patients.

Led by Chinese experts, AHEAD marks a key milestone in China's transition from follower to leader in global dermatology research and AD treatment innovation. This large-scale, multicenter real-world study evaluates abrocitinib's use in Chinese patients with moderate-to-severe AD, including efficacy and treatment patterns. Interim data gathered from 314 patients across 40 Chinese centers confirm abrocitinib's real-world performance in China aligns with global Phase III trial results.

AD, a chronic inflammatory skin disease, is the leading non-fatal skin condition globally, severely impacting patients' physical and mental health. In China, AD cases have surged to over 70 million, posing a major public health challenge. The economic burden is significant, with direct medical costs consuming 12%-18% of household incomes, according to Pfizer China.

Follow China.org.cn on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:    
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from China.org.cnMobileRSSNewsletter
主站蜘蛛池模板: 国产精品久久国产精品99盘 | 最新版天堂中文在线| 人人妻人人做人人爽| 亚洲香蕉在线观看| 成人欧美一区二区三区在线观看| 亚洲欧美日韩另类在线一| 被cao的合不拢腿的皇后| 天天在线欧美精品免费看| 久久精品女人天堂AV麻| 欧美成人免费午夜影视| 厨房娇妻被朋友跨下挺进在线观看| 麻豆91在线播放| 国产爆乳无码一区二区麻豆 | 好吊色青青青国产在线播放 | 国产无套粉嫩白浆在线观看| 一个人看的视频www在线| 最新国产精品亚洲| 亚洲国产成人精品无码一区二区 | 日韩国产欧美精品综合二区| 亚洲sss视频| 男人操女人视频免费| 国产成年女人特黄特色毛片免| √天堂资源地址在线官网 | 亚洲精品字幕在线观看| 色婷婷丁香六月| 国产精品久久精品福利网站| 91精品国产综合久久久久久| 成年人免费看片网站| 亚洲人成网站999久久久综合| 精品国产不卡在线电影| 国产福利在线导航| heyzo北条麻妃久久| 日日碰狠狠添天天爽不卡| 久久国产精品视频| 欧美日韩视频在线观看高清免费网站| 四虎影永久在线观看精品| xxxx性bbbb欧美野外| 天天插在线视频| m.jizz4.com| 天天操天天干天天透| a级黄色片视频|